Publications by authors named "J J Petrozzino"
Introduction: Fresh frozen plasma (FFP) is a frequently used human blood product to reverse the effects of vitamin K antagonists. While FFP is relatively economical, its large fluid volume can lead to hospitalization complications, therefore increasing the overall cost of use.
Materials & Methods: A recently published article by Sarode et al.
An Algorithm to Analyze Cost Heterogeneity using Counterfactual Scenarios in Endovascular versus Open Repair of Abdominal Aortic Aneurysm: Predicting Costs for Subsequent Patients.
J Health Econ Outcomes Res
February 2014
We examined patient-specific predictors of high cost for endovascular (EVAR) and open (OPEN) repair of abdominal aortic aneurysm (AAA). Vascular Study Group of Northern New England data specific to Fletcher Allen Health Care were merged with cost data from the same source. We retrospectively analyzed 389 elective AAA repairs (230 EVAR, 159 OPEN) between 2003 and 2011 to determine clinical characteristics that contribute to membership in the upper quartile of cost (UQC) versus the remaining three quartiles.
View Article and Find Full Text PDFArticle Synopsis
- The study compared the impact of obligatory single embryo transfer (SET) and elective SET on pregnancy outcomes using data from UK IVF treatments between 1991 and 1998.
- Both types of SET resulted in similar rates of clinical pregnancy, live births, and multiple births, with adjusted odds ratios indicating no significant difference in live birth outcomes.
- The findings suggest that obligatory SET is as effective as elective SET for achieving pregnancy and live births while also maintaining a low rate of multiple births, highlighting the need for further research to optimize these outcomes.
Background: Transplantation rates are very low for the broadly sensitized patient (panel reactive antibody [PRA]>80%; HS). Here, we examine the efficacy, outcomes, and cost-effectiveness of desensitization using high-dose intravenous immunoglobulin (IVIG) and rituximab to improve transplantation rates in HS patients.
Methods: From July 2006 to December 2011, 207 HS (56 living donors/151 deceased donors) patients (donor-specific antibody positive, PRA>80%) were desensitized using IVIG and rituximab.